Radiation Necrosis with ADCs and Concurrent Radiotherapy for Brain Metastases

Opinion
Video

Rani Bansal, MD explores recent findings suggesting a risk of radiation necrosis in patients undergoing treatment with ADCs and concurrent radiotherapy for brain metastases and discusses the potential implications for future treatment approaches.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Recent Videos
      Optimizing Maintenance Therapy After First-Line Treatment in HER2+ Metastatic Breast Cancer
      Optimizing Maintenance Therapy After First-Line Treatment in HER2+ Metastatic Breast Cancer
      Current Treatment Approaches in HER2+ Metastatic Breast Cancer
      Current Treatment Approaches in HER2+ Metastatic Breast Cancer
      Complex ES-SCLC Case: Tarlatamab Management Through Toxicity to Clinical Benefit
      Complex ES-SCLC Case: Tarlatamab Management Through Toxicity to Clinical Benefit
      Seamless Transitions: Managing the Inpatient to Outpatient Care Continuum
      Seamless Transitions: Managing the Inpatient to Outpatient Care Continuum
      Future Research Priorities: Optimizing Tarlatamab Administration and Toxicity Management
      Future Research Priorities: Optimizing Tarlatamab Administration and Toxicity Management
      Standardized Toxicity Grading: Institutional Protocols for CRS and ICANS
      Standardized Toxicity Grading: Institutional Protocols for CRS and ICANS
      Differential Toxicity Profile: Tarlatamab vs Traditional Cytotoxic Therapies
      Differential Toxicity Profile: Tarlatamab vs Traditional Cytotoxic Therapies
      The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
      Gene Assay Can Guide Chemo Strategies in Older Breast Cancer Population
      Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
      Targeted Tool May Optimize Infusion Therapy Delivery in Breast Cancer
      Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
      Pivotal Presentations That May Shape the Breast Cancer Standard of Care
      Related Content
      TPS 28 ELEGANT: Elacestrant VS Standard Endocrine Therapy in Women and Men With Node-Positive, Estrogen Receptor-Positive, HER2-Negative, Early Breast Cancer With High Risk of Recurrence in a Global, Multicenter, Randomized, Open-Label Phase 3 Study

      TPS 28 ELEGANT: Elacestrant VS Standard Endocrine Therapy in Women and Men With Node-Positive, Estrogen Receptor-Positive, HER2-Negative, Early Breast Cancer With High Risk of Recurrence in a Global, Multicenter, Randomized, Open-Label Phase 3 Study

      Aditya Bardia, MD, MPH;Virginia Kaklamani, MD, DSc;Joyce A. O’Shaughnessy;Peter Schmid, MD;J. Thaddeus Beck,;Michelino De Laurentiis;Guiseppe Curigliano;Hope S. Rugo, MD;Carlos Barcenas;William J. Gradishar, MD;Michail Ignatiadis;David Cameron;Giulia Tonini;Simona Scartoni;Jennifer Crozier;Leo Viana Nicacio;Tomer Wasserman;Sara M. Tolaney, MD, MPH
      June 18th 2025
      Article
      Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

      Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

      Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
      April 21st 2025
      Podcast

      Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

      TPS 31 Real-World Sacituzumab Govitecan Treatment Patterns and Outcomes in Second-Line or Later Metastatic Triple-Negative Breast Cancer: Leveraging Electronic Health Records and Manual Curation of a US Database

      TPS 31 Real-World Sacituzumab Govitecan Treatment Patterns and Outcomes in Second-Line or Later Metastatic Triple-Negative Breast Cancer: Leveraging Electronic Health Records and Manual Curation of a US Database

      Vikram Gorantla
      June 15th 2025
      Article
      Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

      SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

      Paolo Tarantino, MD;Matteo Lambertini, MD
      January 13th 2025
      Podcast

      Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

      Data from the ELEVATE trial may support elacestrant as an endocrine therapy backbone in ER-positive, HER2-negative metastatic breast cancer.

      Elacestrant Regimens Show Activity in Pretreated ER+/HER2– Breast Cancer

      Chris Ryan
      June 11th 2025
      Article

      Data from the ELEVATE trial may support elacestrant as an endocrine therapy backbone in ER-positive, HER2-negative metastatic breast cancer.

      HER2 Amplicon mRNA Signature May Determine Positive Outcomes With T-DXd in mBC

      HER2 Amplicon mRNA Signature May Determine Positive Outcomes With T-DXd in mBC

      Ariana Pelosci
      June 2nd 2025
      Article

      “Higher pretreatment HER2 amplicon mRNA signature and HER2 protein expression predicted improved outcomes with T-DXd for [metastatic breast cancer],” Paolo Tarantino, MD, PhD, said.